Alpha Tau Medical Gets FDA IDE for cSCC Study
Ticker: DRTSW · Form: 6-K · Filed: Sep 20, 2024 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Sep 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA approval, clinical trial, medical device
TL;DR
FDA greenlights Alpha Tau's IDE for immunocompromised cSCC patients study.
AI Summary
Alpha Tau Medical Ltd. announced on September 20, 2024, that it has received FDA approval for an Investigational Device Exemption (IDE) to begin a multi-center study. This study will investigate the use of their Alpha DaRT® technology in immunocompromised patients suffering from recurrent cutaneous squamous cell carcinoma (cSCC). The study aims to gather crucial data on the efficacy and safety of this novel treatment approach.
Why It Matters
This FDA approval is a significant step for Alpha Tau Medical, potentially paving the way for a new treatment option for a challenging patient population with recurrent cSCC.
Risk Assessment
Risk Level: medium — The company is in the clinical trial phase, and the success of the study is not guaranteed, which carries inherent risks.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Registrant
- FDA (company) — Regulatory body granting approval
- Alpha DaRT® (product) — Investigational technology
- September 20, 2024 (date) — Date of announcement and filing
FAQ
What is the specific indication being studied for Alpha DaRT®?
The study will investigate Alpha DaRT® in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC).
What type of FDA approval did Alpha Tau Medical receive?
Alpha Tau Medical received Investigational Device Exemption (IDE) approval from the FDA.
When was this announcement made?
The announcement was made on September 20, 2024.
What is the purpose of the multi-center study?
The study aims to investigate the use of Alpha DaRT® in immunocompromised patients with recurrent cSCC.
What form was filed with the SEC regarding this announcement?
A Form 6-K was filed with the SEC, reporting the press release about the FDA approval.
Filing Stats: 311 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-09-20 08:35:02
Filing Documents
- ea0215198-6k_alphatau.htm (6-K) — 15KB
- ea021519801ex99-1_alphatau.htm (EX-99.1) — 16KB
- 0001213900-24-080424.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: September 20, 2024 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3